Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3978/j.issn.2218-676X.2015.06.04 http://scihub22266oqcxt.onion/10.3978/j.issn.2218-676X.2015.06.04 C4511498!4511498!26213686     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26213686&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Transl+Cancer+Res 2015 ; 4 (3): 256-69 Nephropedia Template TP {{tp|p=26213686|t=2015. Cancer biomarker discovery and validation |pdf=|usr=}}{{26213686}} gab.com Text Cancer biomarker discovery and validation JO: Transl Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=26213686 #FOAvip With the emergence of genomic profiling technologies and selective molecular targeted therapies, biomarkers play an increasingly important role in the clinical management of cancer patients. Single gene/protein or multi-gene ?signature?-based assays have been introduced to measure specific molecular pathway deregulations that guide therapeutic decision-making as predictive biomarkers. Genome-based prognostic biomarkers are also available for several cancer types for potential incorporation into clinical prognostic staging systems or practice guidelines. However, there is still a large gap between initial biomarker discovery studies and their clinical translation due to the challenges in the process of cancer biomarker development. In this review we summarize the steps of biomarker development, highlight key issues in successful validation and implementation, and overview representative examples in the oncology field. We also discuss regulatory issues and future perspectives in the era of big data analysis and precision medicine. Twit Text FOAVip Cancer biomarker discovery and validation ????Transl Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=26213686 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26213686 #FOAvip English Wikipedia <ref>{{Cite pmid|26213686}}</ref> Cancer biomarker discovery and validation #MMPMID26213686 Goossens N; Nakagawa S; Sun X; Hoshida Y Transl Cancer Res 2015[Jun]; 4 (3): 256-69 PMID26213686show ga With the emergence of genomic profiling technologies and selective molecular targeted therapies, biomarkers play an increasingly important role in the clinical management of cancer patients. Single gene/protein or multi-gene ?signature?-based assays have been introduced to measure specific molecular pathway deregulations that guide therapeutic decision-making as predictive biomarkers. Genome-based prognostic biomarkers are also available for several cancer types for potential incorporation into clinical prognostic staging systems or practice guidelines. However, there is still a large gap between initial biomarker discovery studies and their clinical translation due to the challenges in the process of cancer biomarker development. In this review we summarize the steps of biomarker development, highlight key issues in successful validation and implementation, and overview representative examples in the oncology field. We also discuss regulatory issues and future perspectives in the era of big data analysis and precision medicine. äCancer biomarker discovery and validation (epmc).pdf DeepDyve Pubget Overpricing